Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the Pharmacodynamic Response and Safety of Three Dose Levels of Glymera Injection Following 20 Weeks of Once-Weekly Subcutaneous Dosing in Adult Subjects With Inadequately Treated Type 2 Diabetes Mellitus
Phase of Trial: Phase II
Latest Information Update: 09 Dec 2015
At a glance
- Drugs PB 1023 (Primary) ; Liraglutide
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors PhaseBio Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jun 2013 Results are expected to be reported in the fall of 2013, according to a PhaseBio Pharmaceuticals media release.